Leveraging Olink Proteomics® Proximity Extension Assay (PEA) technology, Azenta Life Sciences’ protein biomarker detection services enable detection and quantification of circulating proteins to provide an in-depth, biological understanding of disease and drug response. Unlike traditional methods, this approach enables high-throughput, simultaneous analysis of proteins with high specificity and sensitivity using minimal sample amounts. Processing is available for research use only (RUO) or can be performed in our CAP-accredited, CLIA-certified laboratory for clinical applications.
For a multiomics approach, this proteomics service can be combined with Azenta’s genomic and transcriptomic solutions to provide a comprehensive understanding of molecular changes contributing to development, disease, and drug response in clinical trials.
|Olink Target 48||Olink Target 96||Olink Explore 3072/384|
|One of the broadest human cytokine inflammation panels available, Olink Target 48 allows for analysis of proteins with the highest relevance for investigation of inflammatory processes and diseases to support clinical trials.||With Olink Target 96, choose from fifteen carefully designed panels built for specific areas of human disease and key biological processes. For researchers working with mouse models, Target 96 Mouse Exploratory is also available.||Comprised of eight 384-plex human disease focused panels, Olink Explore is both flexible and scalable; you may run the entire library or focus on one or more of the 384-plex panels.|
Use the Target 48 cytokine panel to elucidate:
These panels are organized into four disease areas:
Genomics, transcriptomics, and proteomics individually provide unique and crucial insights into the inner workings of human cells. Collectively, these –omics tools can provide detailed insights into relationships and patterns to help you accelerate and expand your search for drug targets.
Custom bioinformatics analysis and reports are available. Please contact us about how we can customize your analysis to answer your biological question.
Current proteomics technologies often present limitations in terms of throughput, specificity, and cost. However, new innovations, such as Olink Proteomics’ proximity extension assay (PEA) technology, are overcoming these challenges by enabling hundreds to thousands of proteins to be measured in a single sample. In this blog, discover how Azenta is leveraging PEA technology for protein biomarker discovery, its applications, and how it can complement genomics data to accelerate drug development.
Azenta is a certified service provider for Illumina and other cutting-edge NGS platforms. For information on our NGS platforms, as well as recommended configurations of your projects, please visit the NGS Platforms page. Azenta does not guarantee data output or quality for sequencing only projects.